

Mediclinic International plc  
 (Incorporated in England and Wales)  
 Company Number: 08338604  
 LSE Share Code: MDC  
 JSE Share Code: MEI  
 NSX Share Code: MEP  
 ISIN: GB00B8HX8Z88  
 LEI: 2138002S5BSBIZTD5I60  
 South African income tax number: 9432434182  
 ('Mediclinic', the 'Company', or the 'Group')

5 August 2022

**NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM**

This notification sets out the details of awards over ordinary shares in Mediclinic ('Shares') granted to directors and other persons discharging managerial responsibilities ('PDMRs') on 5 August 2022 under the Company's short-term incentive scheme ('STI') and long-term incentive plan ('LTIP'), in accordance with the Remuneration Policy and share plan rules approved by shareholders at the annual general meeting of the Company held on 28 July 2022.

Name	Director/ PDMR	Number of Shares awarded under the STI	Number of Shares awarded under the LTIP
Dr Carel Aron van der Merwe	Director	74 718	237 716
Petrus Jurgens Myburgh	Director	47 488	148 319
David John Hadley	PDMR	n/a	58 369
Gert Cornelis Hattingh	PDMR	n/a	28 716
Dr Dirk Cornelius le Roux	PDMR	n/a	22 450
Dr Daniel Liedtke	PDMR	n/a	52 074
Magnus Oetiker	PDMR	n/a	51 945
Koert Hendrik Stefanus Pretorius	PDMR	n/a	30 055
Dr René Toua	PDMR	n/a	23 594
Dr Tyson Bruno Welzel	PDMR	n/a	40 608
Greg van Wyk	PDMR	n/a	27 270

The above awards were granted for nil consideration and are based on the closing price of a Share on 4 August 2022, which equates to £4.98 per Share.

<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	<b>Dr Carel Aron van der Merwe</b>

<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Group Chief Executive Officer – Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
<b>4.1</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short-Term Incentive scheme
c)	Price(s) and volume(s)	Price(s)                      Volume(s) £nil                              74 718
d)	Aggregated information	
	Aggregated volume	74 718
	Price	£nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue
<b>4.2</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s)                      Volume(s) £nil                              237 716
d)	Aggregated information	
	Aggregated volume	237 716
	Price	£nil

e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them		
a)	Name	Petrus Jurgens Myburgh	
2.	Reason for the notification		
a)	Position / status	Group Chief Financial Officer – Mediclinic International plc	
b)	Initial notification / amendment	Initial Notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Mediclinic International plc	
b)	LEI	2138002S5BSBIZTD5I60	
4.1	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares	
	Identification Code	GB00B8HX8Z88	
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short-Term Incentive scheme	
c)	Price(s) and volume(s)	Price(s) £nil	Volume(s) 47 488
d)	Aggregated information		
	Aggregated volume	47 488	
	Price	£nil	
e)	Date of the transaction	5 August 2022	
f)	Place of the transaction	Outside a trading venue	
4.2	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares	
	Identification Code	GB00B8HX8Z88	
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan	

c)	Price(s) and volume(s)	Price(s) £nil	Volume(s) 148 319
d)	Aggregated information		
	Aggregated volume	148 319	
	Price	£nil	
e)	Date of the transaction	5 August 2022	
f)	Place of the transaction	Outside a trading venue	

1.	Details of PDMR / person closely associated with them		
a)	Name	David John Hadley	
2.	Reason for the notification		
a)	Position / status	Chief Executive Officer – Mediclinic Middle East	
b)	Initial notification / amendment	Initial Notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Mediclinic International plc	
b)	LEI	2138002S5BSBIZTD5I60	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares	
	Identification Code	GB00B8HX8Z88	
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company’s Long-Term Incentive Plan	
c)	Price(s) and volume(s)	Price(s) £nil	Volume(s) 58 369
d)	Aggregated information		
	Aggregated volume	58 369	
	Price	£nil	
e)	Date of the transaction	5 August 2022	
f)	Place of the transaction	Outside a trading venue	

<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	<b>Gert Cornelis Hattingh</b>
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Group Chief Governance Officer – Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) £nil                      Volume(s) 28 716
d)	Aggregated information	
	Aggregated volume	28 716
	Price	£nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	<b>Dr Dirk Cornelius le Roux</b>
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Group Chief Information Officer – Mediclinic International plc
b)	Initial notification / amendment	Initial Notification

<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s)                      Volume(s) £nil                              22 450
d)	Aggregated information	
	Aggregated volume	22 450
	Price	£nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	<b>Dr Daniel Liedtke</b>
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Chief Executive Officer: Hirslanden
b)	Initial notification / amendment	Initial Notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	

a)	Description of the financial instrument  Identification Code	Ordinary Shares  GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s)                      Volume(s) £nil                              52 074
d)	Aggregated information  Aggregated volume  Price	  52 074  £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	Magnus Oetiker
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Group Chief Strategy Officer – Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument  Identification Code	Ordinary Shares  GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s)                      Volume(s) £nil                              51 945

d)	Aggregated information	
	Aggregated volume	51 945
	Price	£nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	<b>Koert Hendrik Stefanus Pretorius</b>
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Group Chief Operating Officer – Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) £nil                      Volume(s) 30 055
d)	Aggregated information	
	Aggregated volume	30 055
	Price	£nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue



<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	Dr René Toua
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Group Chief Clinical Officer – Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) £nil                      Volume(s) 23 594
d)	Aggregated information	
	Aggregated volume	23 594
	Price	£nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

<b>1.</b>	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	Dr Tyson Bruno Welzel
<b>2.</b>	<b>Reason for the notification</b>	
a)	Position / status	Group Chief Innovation Officer – Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc

b)	LEI	2138002S5BSBIZTD5I60
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) £nil                      Volume(s) 40 608
d)	Aggregated information	
	Aggregated volume	40 608
	Price	£nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	<b>Details of PDMR / person closely associated with them</b>	
a)	Name	Greg van Wyk
2.	<b>Reason for the notification</b>	
a)	Position / status	Chief Executive Officer: Mediclinic Southern Africa
b)	Initial notification / amendment	Initial Notification
3.	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument	Ordinary Shares
	Identification Code	GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan

c)	Price(s) and volume(s)	Price(s) £nil	Volume(s) 27 270
d)	Aggregated information		
	Aggregated volume	27 270	
	Price	£nil	
e)	Date of the transaction	5 August 2022	
f)	Place of the transaction	Outside a trading venue	

### About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

#### Company Secretary, Link Company Matters Limited

Caroline Emmet  
+44 (0)333 300 1930

#### Investor Relations

James Arnold, Head of Investor Relations  
[ir@mediclinic.com](mailto:ir@mediclinic.com)  
+44 (0)20 3786 8181

#### Media queries

FTI Consulting  
Ben Atwell/Ciara Martin – United Kingdom  
+44 (0)20 3727 1000  
Sherryn Schooling – South Africa  
+27 (0)21 487 9000

**Registered address:** 6<sup>th</sup> Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

**Website:** [www.mediclinic.com](http://www.mediclinic.com)

**Corporate broker (United Kingdom):** Morgan Stanley & Co International plc and UBS Investment Bank

**JSE sponsor (South Africa):** Rand Merchant Bank (A division of FirstRand Bank Limited)

**NSX sponsor (Namibia):** Simonis Storm Securities (Pty) Ltd